BLAINJECTIONINJECTABLE
Approved
Aug 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
35
Intelligence
5/8 — Good Coverage
REPATHA (evolocumab) by Amgen is pcsk9 inhibitors [moa]. Approved for pcsk9 inhibitor [epc]. First approved in 2015.
Mechanism of Action
PCSK9 Inhibitors
Pharmacologic Class:
PCSK9 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (35)
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
Started Jan 2026
400 enrolled
Healthy ParticipantsPharmacokinetics
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Started Dec 2024
69 enrolled
Dyslipidemias
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
Started Aug 2024
10 enrolled
Metastatic Renal Cell Carcinoma
Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism
Started Feb 2024
8 enrolled
Acute Metabolic Effects of Evolocumab and Atorvastatin
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
Started Dec 2022
7,000 enrolled
Major Cardiovascular EventEstablished Atherosclerotic Cardiovascular Disease
Worked on REPATHA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.